260 related articles for article (PubMed ID: 28870594)
21. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
22. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
[TBL] [Abstract][Full Text] [Related]
23. New drugs for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2012 Nov; 54(1403):89-91. PubMed ID: 23183318
[No Abstract] [Full Text] [Related]
24. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
25. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
26. Teriflunomide for multiple sclerosis in real-world setting.
Elkjaer ML; Molnar T; Illes Z
Acta Neurol Scand; 2017 Nov; 136(5):447-453. PubMed ID: 28321835
[TBL] [Abstract][Full Text] [Related]
27. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Scott LJ
Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
[TBL] [Abstract][Full Text] [Related]
31. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
[TBL] [Abstract][Full Text] [Related]
32. Rebound syndrome in two cases of MS patients after teriflunomide cessation.
Labauge P; Ayrignac X; Prin P; Charif M; Carra-Dalliere C
Acta Neurol Belg; 2022 Oct; 122(5):1381-1384. PubMed ID: 35802339
[No Abstract] [Full Text] [Related]
33. Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.
Fuerte-Hortigón A; López Ruiz R; Hiraldo J; Sánchez Fernández F; Dotor García-Soto J; Páramo MD; Ruiz-Peña JL; Navarro-Mascarell G; Eichau S
Mult Scler Relat Disord; 2020 Jun; 41():102017. PubMed ID: 32120027
[TBL] [Abstract][Full Text] [Related]
34. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
35. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
Zivadinov R; Bergsland N; Hagemeier J; Carl E; Kolb H; Hojnacki D; Weinstock-Guttman B
J Neurol Sci; 2018 May; 388():175-181. PubMed ID: 29627017
[TBL] [Abstract][Full Text] [Related]
36. Digestive side-effects with teriflunomide: Thoughts on lactose.
Lebrun C; Bertagna M; Bresch S; Cohen M
Rev Neurol (Paris); 2018 Dec; 174(10):722-725. PubMed ID: 30409479
[TBL] [Abstract][Full Text] [Related]
37. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN; Alifirova VM; Lukashevich IG; Goncharova ZA; Greshnova IV; Zaslavsky LG; Kotov SV; Malkova NA; Mishin GN; Parshina EV; Poverennova IY; Prakhova LN; Sivertseva SA; Smagina IV; Totolyan NA; Trinitatsky YV; Trushnikova TN; Khabirov FA; Chefranova JY; Shchur SG; Dudin VA; Pokhabov DV; Artemeva AV; Eremeeva AV; Linkova YN; Zinkina-Orikhan AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):86-96. PubMed ID: 38676683
[TBL] [Abstract][Full Text] [Related]
38. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Confavreux C; Li DK; Freedman MS; Truffinet P; Benzerdjeb H; Wang D; Bar-Or A; Traboulsee AL; Reiman LE; O'Connor PW;
Mult Scler; 2012 Sep; 18(9):1278-89. PubMed ID: 22307384
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
